Bullous Pemphigoid that Developed During Nemolizumab Treatment for Atopic Dermatitis: Two Case Reports

Michie Katsuta,Ryoichi Kamide,Yozo Ishiuji,Yoshimasa Nobeyama,Akihiko Asahina

DOI: https://doi.org/10.2340/actadv.v104.40634

2024-09-02

Abstract:Abstract is missing (Short communication)

dermatology

What problem does this paper attempt to address?

A case of systemic lupus erythematosus complicated with pemphigus vulgaris

Huai-yuan XU,Zhong-fa L(U)

DOI: https://doi.org/10.35541/cjd.20210239

2008-01-01

Abstract: A case of systemic lupus erythematosus complicated by pemphigus vulgaris is reported. A 42-year-old female patient presented facial red macules with the joints pain on the limbs for 4 years. She was photosensitive with hematologic abnormal, positive antinuclear antibody, positive antibody to ds-DNA. She got relapsing erosions of mucous membranes in mouth for 2 years. Then extensive, generalized bullae developed, and the bullae soon ruptured to form erosions. The diagnosis of pemphigus vulgaris was confirmed by clinical, histological and immunofluorescent evidences.
The Treatment of Refractory Atypical Bullous Pemphigoid with Generalized Eczema and Intense Pruritus with Dupilumab

Wei Li,Sheng Cai,Xiao‐Yong Man

DOI: https://doi.org/10.1111/dth.15243

2021-01-01

Dermatologic Therapy

Abstract:The data that support the findings of this study are available from the corresponding author upon reasonable request.
Case Report: The many faces of bullous pemphigoid

Laura Rechtien,Lukas Sollfrank,Yannick Foerster,Carola Berking,Michael Sticherling

DOI: https://doi.org/10.3389/fimmu.2023.1272742

2023-10-12

Abstract:The pemphigoid group comprises a number of bullous skin diseases with autoantibodies against different constituents of the basement membrane zone that result in subepidermal detachment and clinically characteristic tense blisters, erosions, urticarial erythema, and itching. Apart from the most frequent type of bullous pemphigoid with antibodies against BP180, which is found predominantly in elderly patients, the disease may present at other ages and different pathogenic conditions. Here, four cases are presented of young age (3 months and 25, 34, and 46 years) and in association with vaccination, pregnancy, or metastatic cancer. Though anti-BP180 was found in all cases, a different pathogenic background may be found in any of them, resulting in characteristic clinical manifestation, yet demanding specifically adapted therapeutic approaches.
Case Report: Pemphigoid Nodularis-Five Patients With Many Years of Follow-Up and Review of the Literature

Konrad Szymanski,Alicja Adaszewska,Beata Jakubowska,Cezary Kowalewski,Ewelina Pietrzyk,Katarzyna Wozniak

DOI: https://doi.org/10.3389/fimmu.2022.885023

2022-04-12

Abstract:Pemphigoid nodularis is a rare form of pemphigoid that joins the clinical picture of prurigo nodularis and the immunological features of bullous pemphigoid, which is therapeutically challenging. Here, we analyze five female patients with a long-lasting course of nodular pemphigoid in terms of clinical and immunological characteristics and therapy. All the patients fulfilled clinical and immunological criteria of nodular pemphigoid. We applied numerous techniques allowing the proper diagnosis: direct and indirect immunofluorescence, salt split skin, ELISA, BIOCHIP, and fluorescence overlay antigen mapping using laser scanning confocal microscopy. Our study showed that 4 of 5 patients fulfilled the clinical and immunological criteria of nodular bullous pemphigoid. Two out of 4 patients presented exclusively nodular lesions; in the other two patients, blisters and erythematous lesions preceded prurigo-like lesions by a few years. The remaining patient had clinical and immunological criteria of nodular mucous membrane pemphigoid, presenting oral erosions, scarring conjunctivitis, and numerous disseminated nodules on the skin. All the patients were treated with multiple medicines; however, it was observed that the use of clobetasol propionate on the entire body plus antidepressants best controlled the disease. Pemphigoid nodularis mainly occurs in elderly women. In cases with coexisting psychological problems, antidepressants should be considered as an important complementary therapy to the basic one with clobetasol propionate.
Sulfamethoxypyridazine-responsive pemphigoid nodularis: a report of two cases

J E Gach,N J E Wilson,F Wojnarowska,A Ilchyshyn

DOI: https://doi.org/10.1016/j.jaad.2004.07.062

Abstract:Pemphigoid nodularis is a chronic and uncommon variant of bullous pemphigoid. The condition is characterized by the presence of prurigo nodularis-like lesions, possible history of blistering, and immunohistochemical findings of bullous pemphigoid. These patients are often unresponsive to conventional therapy with potent topical and systemic steroids and different immunosuppressive agents used alone or in combination. We describe two cases of pemphigoid nodularis treated successfully with sulfamethoxypyridazine without any adverse effects.
Pemphigoid nodularis: a report of three cases and review of the literature

S Cliff,C A Holden

Abstract:Many variants of bullous pemphigoid have been reported, some of which are clinically very atypical. One of the rarest variants is pemphigoid nodularis. We report three patients with this distinct entity. In all three cases patients initially presented with prurigo-like lesions and in one case nodular lesions preceded the onset of blistering by many months. Direct immunofluorescence was positive in all cases, with linear basement membrane zone deposition of IgG and C3. Circulating IgG antibasement membrane antibody was detected in two cases, and in these two patients on salt-split immuno-fluorescence the antibodies bound to the roof of the bullae.
Atypical Presentation of Severe Bullous Pemphigoid: A Case Report

Tinotenda Sekeramayi,Sara Ruter

Abstract:Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disorder. Typically, patients will present with tense bullae and intense generalized pruritus with a skin biopsy demonstrating subepidermal split with eosinophils and a direct immunofluorescence highlighting autoantibodies against the basement membrane zone. Prognosis varies, and treatment involves an assessment of the severity of disease to determine whether to initiate topical or systemic immunosuppressive agents. We present an atypical presentation of BP that presented as a 3-to-4-week duration of pruritic small vesicular lesions in the upper chest, scabbed circular lesions along the upper extremity and pinnas of bilateral ear. Initially thought to be herpes zoster infection initially treated with valacyclovir for a week following a prior concern of a concomitant superficial skin infection with cephalexin and prednisone. With no clinical improvement, tissue biopsy was performed that confirmed bullous pemphigoid and treatment with steroid taper, doxycycline, and triamcinolone acetonide 0.1% cream was started. The aim of this case report is to present an atypical presentation of BP and to highlight maintaining a high index of suspicion of BP in patients presenting with disseminated significantly pruritic lesions.
Pemphigoid nodularis: two case studies and analysis of autoantibodies before and after the development of generalized blistering

Hirotsugu Tashiro,Harue Arai,Takashi Hashimoto,Shinichiro Takezaki,Seiji Kawana

DOI: https://doi.org/10.1272/jnms.72.60

Abstract:We report 45- and 61-year-old women with generalized prurigo nodularis-like eruption whose clinical, histologic and immunopathologic features were consistent with the diagnosis of pemphigoid nodularis. In one case, nodular lesions preceded the onset of generalized blistering by two years and in the other, no definite blister nor erosion was seen except for some appearing on the soles during the course of the disease. Western immunoblotting of EDTA-separated epidermal extracts revealed that the 230-kD bullous pemphigoid (BP) antigen was recognized by circulating autoantibodies in the patient sera, but the 180-kD BP antigen was not. The 180-kD BP antigen was recognized weakly by immunoblotting of the 180-kD BP antigen NC16a domain fusion protein, which shows high detection sensitivity. These findings suggested that weak reactivity of autoantibodies with either whole or a part of the 180-kD BP antigen molecule in some way accounts for negligible or localized blister-formation in this disorder. However, no particular change was noted in the reactivity with 180-kD BP antigen between the patient serum obtained before and after the development of generalized blistering. It is possible that different factors from the changes in serum reactivity with BP antigens may be involved in initiating generalized blistering.
A case of bullous pemphigoid following administration of anti‐IL‐31 receptor A antibody

Ryosuke Masuyuki,Emi Sato,Shinichi Imafuku

DOI: https://doi.org/10.1111/1346-8138.17171

IF: 3.468

2024-03-22

The Journal of Dermatology

Abstract:Bullous pemphigoid (BP), an autoimmune bullous dermatosis, occurs predominantly in older individuals. Nemolizumab, a humanized monoclonal antibody against the interleukin (IL)‐31 receptor A, is used to treat severe atopic dermatitis (AD) in Japan. However, it can cause several adverse events, such as exacerbation of AD, erythema, and eosinophilia. Herein, we describe a case of prurigo‐type AD developing BP after nemolizumab administration. A 62‐year‐old man with prurigo‐type AD and asthma presented with serious, refractory itching. After nemolizumab injection, his pruritus was relieved for 2 days. However, on day 3, erythema with blisters and erosions suddenly appeared throughout his body. Pathological examination showed typical BP and the patient's serum anti‐BP180‐NC16a antibody level was 882.5 U/mL. Oral prednisolone (PSL) was initiated and nemolizumab was never used again. Despite high‐dose PSL, new blisters continued to develop, with a rapid elevation of anti‐BP180‐NC16a antibodies to 6930 U/mL. Adding high‐dose cyclosporine and intravenous gamma globulin reduced new blister formation after 9 weeks, and PSL and cyclosporine were gradually tapered. Dupilumab, an anti‐IL‐4 receptor antibody, was initiated after 16 weeks, resulting in continued remission without PSL and cyclosporine. The sudden occurrence of BP in this case suggested that the patient had occult BP before the nemolizumab initiation and that nemolizumab exacerbated BP and made it overt. Blocking the IL‐31 pathway may exacerbate inflammation in AD or BP, resulting in the acceleration of blister formation. This may be countered by blocking the IL‐4/13 pathway with dupilumab. To our knowledge, this is the first case of nemolizumab‐exacerbated BP.

dermatology
Unusual variants of pemphigoid: from pruritus to pemphigoid nodularis

J S Ross,P H McKee,N P Smith,H Shimizu,W A Griffiths,B S Bhogal,M M Black

DOI: https://doi.org/10.1111/j.1600-0560.1992.tb01661.x

Abstract:We report three patients with pemphigoid nodularis. Patients were females aged 76, 71 and 50 years, and all had features of bullous pemphigoid together with prurigo-like lesions at some stage of their illness. In two cases, nodular lesions preceded the onset of blistering by some months. Blisters arose on normal skin and in one patients also at sites of prurigo lesions. Routine histology of bullous lesions revealed the presence of subepidermal blisters. Electron microscopy performed in two cases confirmed the level of split to be through the lamina lucida. Direct immunofluorescence in all cases was positive, with linear basement membrane zone deposition of IgG and C3. Circulating IgG anti-basement membrane antibody was also detected in all patients, and in two, immunoblotting revealed a single antigen of 220 kD.
Pemphigoid nodularis - rare presentation of bullous pemphigoid: A case report and literature review

Corina Vornicescu,Simona Corina Șenilă,Rodica Cosgarea,Elisabeta Candrea,Alexandra Dana Pop,Loredana Ungureanu

DOI: https://doi.org/10.3892/etm.2018.7057

Abstract:Pemphigoid nodularis (PN) is a rare clinical variant of bullous pemphigoid characterized by the presence of nodular prurigo-like lesions and pemphigoid blisters. The diagnosis is confirmed by direct immunofluorescence (DIF)/ indirect immunofluorescence (IIF) and immunoserology tests. For some patients, with long mean duration of symptoms, the correct diagnosis of PN is delayed because the disease is not recognized. We present a case and summarize the reported characteristics of PN. The search in MEDLINE database, after selection, resulted in 36 articles presenting 47 cases of PN. Between published cases a female predominance was noted (female to male ratio of 1.8:1), almost half of the reported patients were non-Caucasian, and the mean age at presentation was 66.2 years. The mean duration until the diagnosis was almost 2 years. Sixteen patients also had other autoimmune diseases. Twenty-two patients developed vesicles/bullae/urticarial plaques before or after the diagnosis. Peripheral eosinophilia and high levels of serum total IgE were reported in 10.6 and 27.2% of patients, respectively. ELISA for either BP180, BP230 or both were positive in all tested cases. DIF and IIF microscopy were positive overall in 100 and 92.3% of cases, respectively. Corticosteroids, either topical or systemic, were the most efficient therapeutic option, although many others were used. PN remains a diagnostic and therapeutic challenge in elderly patients with unexplained refractory chronic pruritus associated with papulo-nodular lesions.
Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature

Maleck Saleh,Matthew Reedy,Helen Torok,Joshua Weaver

2021-04-15

Abstract:Bullous pemphigoid is an autoimmune skin disease that results in formation of pruritic blisters. Most cases are treated with a combination of systemic and topical corticosteroids as well as other immunomodulatory drugs. Dupilumab is a fully human monoclonal antibody that acts as an antagonist against IL4Ra traditionally used in the treatment of atopic dermatitis. We present an 80-year-old man with moderate to severe bullous pemphigoid successfully treated with dupilumab.
Pemphigoid Nodularis: A Case Report and The Review of Literatures

叶庭路,吴铁强,顾有守,潘慧清,陈永峰

DOI: https://doi.org/10.3969/j.issn.1674-8468.2010.02.023

2010-01-01

Abstract:Pemphigoid nodularis is an uncommon variant of bullous pemphigoid. The condition is characterized by the presence of prurigo nodularis-like lesions, history of blistering, and immunohistochemical findings of bullous pemphigoid in both prurigo nodularis-like and blistering lesions. We reported a typical case and review previous published literatures for causative agent, mechanism, clinical features, diagnosis and treatment of this condition.
Widespread dermal ulcerations and bullae

Jay Wofford,Mahir Patel,Allison Readinger,Alan Menter

DOI: https://doi.org/10.1080/08998280.2012.11928814

Abstract:Bullous pemphigoid is an autoimmune disease of the skin characterized by large, tense bullae resulting in significant morbidity in affected individuals. The diagnosis of bullous pemphigoid may present challenges due to clinical similarities with various other bullous eruptions. Frequently, epidemiological features can provide clues to the diagnosis of bullous pemphigoid, with histologic analysis commonly required for definitive diagnosis. This case study illustrates the typical clinical and histologic findings seen in bullous pemphigoid patients and briefly discusses the differential diagnosis. An in-depth understanding of the intricate pathophysiology is essential in order to educate patients. After diagnosis and appropriate workup, an array of treatment approaches, including topical and systemic corticosteroids, immunosuppressive agents, antibiotics, chemotherapeutic agents, and even monoclonal antibodies, may be utilized individually or in combination to achieve an optimal therapeutic response.
Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature

Edward M Klepper,Howard N Robinson

DOI: https://doi.org/10.5070/D327955136

2021-09-15

Abstract:Immune checkpoint inhibitors, a relatively new class of drugs, are used to treat a variety of malignancies. These drugs have a known association with cutaneous side effects, such as bullous pemphigoid. Bullous pemphigoid is a pruritic blistering disorder that is caused by autoantibodies forming against the basement membrane of the epidermis. New research has shown that interleukin-4, interleukin-13, and eosinophils play a significant role in the pathogenesis of bullous pemphigoid. Dupilumab, an IL4 alpha receptor antagonist has been shown to reduce IL4 and IL13 in atopic dermatitis. We present a case of nivolumab-induced bullous pemphigoid that was successfully treated with dupilumab.
Atypical presentations of bullous pemphigoid: Clinical and immunopathological aspects

Emanuele Cozzani,Giulia Gasparini,Martina Burlando,Francesco Drago,Aurora Parodi

DOI: https://doi.org/10.1016/j.autrev.2015.01.006

Abstract:Bullous pemphigoid may occur in extremely variegated manners, misleading even experienced dermatologists. Indeed the type and/or distribution of lesions may be unusual. Furthermore, there may be an atypical demographic profile of patients, a different clinical course and a different responsiveness to therapy. Up to 20% of the cases the onset is characterized by a non-bullous phase, lasting weeks, months or in particular cases remaining the only manifestation of the disease. During this early phase lesions are generally pruritic erythematous, eczematous or urticarial; however, lesions may also resemble polycyclic, targetoid, nodular or lichenoid lesions. These atypical lesions may also coexist with typical bullae. Other atypical presentations include a vesicular eruption and an erythroderma. Manifestations in children differ from adult forms, presenting an exclusive genital involvement in 50% of cases or a preponderant involvement of the face, the palms and the soles. Rarely bullous pemphigoid is confined to certain body areas, due to particular triggering factors or to a lower disease activity. Therefore, the need to formulate universally recognized diagnostic criteria is increasingly evident, especially for atypical bullous pemphigoid. Direct immunofluorescence of perilesional skin and detection of circulating autoantibodies are mandatory in the diagnosis, especially when the clinical presentation is doubtful.
Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options

Nina van Beek,Detlef Zillikens,Enno Schmidt

DOI: https://doi.org/10.3238/arztebl.m2021.0136

2021-06-18

Abstract:Background: Bullous autoimmune dermatoses are a clinically and immunopatho - logically heterogeneous group of diseases, characterized clinically by blisters or erosions of the skin and/or mucous membranes. In Germany, their prevalence is approximately 40 000 cases nationwide, and their incidence approximately 20 new cases per million people per year. Methods: This review is based on publications that were retrieved by a selective search of the literature focusing on the current German and European guidelines. Results: Recent years have seen the publication of guidelines, controlled prospective clinical trials, and multicenter diagnostic studies improving both diagnosis and therapy. Specific monovalent and multivariate serological test systems and pattern analysis of tissue-bound autoantibodies allow identification of the target antigens in 80-90% of patients. This enables the precise classification of disease entities, with implications for treatment selection and disease outcome. In 2019, the anti-CD20 antibody rituximab was approved by the European Medicines Agency for the treatment of moderate and severe pemphigus vulgaris, with an ensuing marked improvement in the care of the affected patients. To treat mild and moderate bullous pemphigoid, topical clobetasol proprionate is recommended, in severe disease, combined with systemic treatment, i.e. usually (a) prednisolone p.o. at an initial dose of 0.5mg/kg/d , (b) an immunomodulant, e.g. dapsone or doxycycline, or (c) prednisolone plus an immunomodulant. Conclusion: The early recognition and precise diagnostic evaluation of bullous autoimmune dermatoses now enables improved, often interdisciplinary treatment, in accordance with the available guidelines. Current research projects are focused on new treatment approaches, an improved understanding of the underlying pathophysiology, and further refinements of diagnostic techniques.
Use of dupilumab for recalcitrant bullous pemphigoid: A case report

Jillian Lamb,Kerri Purdy,Ashley Sutherland

DOI: https://doi.org/10.1177/2050313X241274855

2024-08-22

Abstract:Bullous pemphigoid is an autoimmune blistering disease affecting the dermo-epidermal junction, most commonly seen in older patients. First-line treatment includes systemic, topical corticosteroids and/or steroid-sparing immunosuppressants. Treatment with these medications may be limited by their safety profile. Dupilumab is a humanized monoclonal antibody targeting interleukin-4 and interleukin-13 cytokines currently indicated for moderate-to-severe atopic dermatitis, severe asthma, chronic rhinosinusitis with nasal polyposis, and moderate-to-severe prurigo nodularis. We report a case of a patient with recalcitrant bullous pemphigoid effectively treated with dupilumab.
Bilateral localized bullous pemphigoid in a young adult patient: A case report

Pedram Nourmohammadpour,Marwa Akhdar,Alireza Ghanadan,Amir Abbas Peymanfar,Fatemeh Saberi,Mahsa Keshavarz-Fathi

DOI: https://doi.org/10.1177/2050313X231190730

2023-07-31

Abstract:Bullous pemphigoid is the most common autoimmune subepidermal blistering disease, which typically presents in the elderly. Localized bullous pemphigoid is a rare variant of bullous pemphigoid, with only about 100 cases reported up to date. In this report, we describe a 32-year-old healthy male patient with bilateral hemorrhagic bullae and erosive lesions limited to the lower extremities. A biopsy for hematoxylin and eosin stain and direct immunofluorescence established the diagnosis of bullous pemphigoid. The blistering responded well to oral and topical steroids. The exact etiology of this rare variant of bullous pemphigoid remains unknown, leading to ongoing debates and numerous suggested hypotheses.
Novel Onset of Cutaneous Lupus Erythematosus Induced by Pembrolizumab

Dimitrii Pogorelov,Heribert Strotkötter,Vesna Bjelic-Radisic,Ulrich Wesselmann,Jonas Hübinger,Simona Sabulyte,Silke C. Hofmann,Galina Balakirski

DOI: https://doi.org/10.2340/actadv.v104.40801

2024-09-30

Abstract:Abstract is missing (Short Communication)

dermatology

Bullous Pemphigoid that Developed During Nemolizumab Treatment for Atopic Dermatitis: Two Case Reports

A case of systemic lupus erythematosus complicated with pemphigus vulgaris

The Treatment of Refractory Atypical Bullous Pemphigoid with Generalized Eczema and Intense Pruritus with Dupilumab

Case Report: The many faces of bullous pemphigoid

Case Report: Pemphigoid Nodularis-Five Patients With Many Years of Follow-Up and Review of the Literature

Sulfamethoxypyridazine-responsive pemphigoid nodularis: a report of two cases

Pemphigoid nodularis: a report of three cases and review of the literature

Atypical Presentation of Severe Bullous Pemphigoid: A Case Report

Pemphigoid nodularis: two case studies and analysis of autoantibodies before and after the development of generalized blistering

A case of bullous pemphigoid following administration of anti‐IL‐31 receptor A antibody

Unusual variants of pemphigoid: from pruritus to pemphigoid nodularis

Pemphigoid nodularis - rare presentation of bullous pemphigoid: A case report and literature review

Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature

Pemphigoid Nodularis: A Case Report and The Review of Literatures

Widespread dermal ulcerations and bullae

Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature

Atypical presentations of bullous pemphigoid: Clinical and immunopathological aspects

Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options

Use of dupilumab for recalcitrant bullous pemphigoid: A case report

Bilateral localized bullous pemphigoid in a young adult patient: A case report

Novel Onset of Cutaneous Lupus Erythematosus Induced by Pembrolizumab